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The three classic autoimmune liver diseases are recognised based on identifying varying 
clinical, laboratory, histological and radiological features which collectively classify patients.  
In the absence of defined aetiological factors it is recognised that disease spectrum is broad, 
and, in this context, it is not infrequent for disease boundaries to be blurred, leading to 
overlapping features which may be present at the time of diagnosis, or may appear later in 
the course of disease. Given the absence of accepted diagnostic criteria for overlap/cross-
over syndromes, alongside weak data for intervention, it is recommended that a multi-
disciplinary, patient-specific approach is used to establish individual treatment pathways. 
  































































Confidential: For Review Only
 3
INTRODUCTION 
Autoimmune liver disease covers a spectrum of uncommon but important liver diseases 
including primary biliary cirrhosis/cholangitis (PBC), autoimmune hepatitis (AIH) and primary 
sclerosing cholangitis (PSC); each with their own specific classifying criteria (1,2). Whilst 
most patients meet diagnostic criteria for only one condition, some will have features of 
more than one condition presenting either simultaneously or sequentially. Such overlap 
presentations do not reflect distinct disease processes but are better considered as 
presentations that highlight the breadth of disease manifestation and severity.  In those that 
have a distinct cross-over from one autoimmune liver disease to another, it may be 
considered as the development of a second autoimmune liver disease in the liver, just as 
patients with autoimmunity generally are prone to new autoimmune manifestations over 
time. Given the relatively rare nature of overlap syndromes, and with no randomised data 
to guide treatment, management of these patients can be challenging. This clinical review 
addresses competencies laid out in 2E of the 2010 UK Gastroenterology curriculum (Box 1) 
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Box 1 – Gastroenterology curriculum 2010 competency  
Auto-immune liver disease including autoimmune hepatitis, PBC, PSC and overlap 
syndromes 
• Recognise and appropriately investigate patients 
• Appreciate and understand that this range of liver disease is frequently under 
diagnosed and may have been inappropriately managed 
• Select appropriate immunomodulatory therapy, have awareness of side effects, and 
when they may well require specialist care 
• Respond urgently to the management challenge of these severe and often acute 
diseases and involve more specialist services where required.  
 
BACKGROUND  
In their classic description, PBC and AIH are two distinct autoimmune liver diseases, each 
with their own clinical, biochemical, immunological and histopathological features (Table 1), 
as well as treatment response. In the majority of cases, distinguishing between a diagnosis 
of PBC and one of AIH is without strain but for a minority of patients who have features of 
more than one condition, either at the time of first presentation or over their disease 
course, the diagnostic process and treatment plan can be challenging. This is a broader 
reflection that many mechanisms underpinning liver and biliary injury in patients with 
autoimmune liver disease are shared. 
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Table 1 - Characteristics of PBC and AIH 
 Primary biliary cholangitis/ 
cirrhosis 
Autoimmune hepatitis  
Demographics  Female: male (10:1) 
Typically age >40 
Female: male (3:1) 
All age groups 
Biochemical profile  Cholestasis Hepatitic  
Autoantibody profile AMA, gp210 sp100, anti-
centromere 
ANA, SMA, anti-F-actin, anti-SLA, 
anti LKM, anti LC 
Immunoglobulin profile  IgM IgG 
Biopsy features  Lymphocytic cholangitis 
with ductopaenia, 
granulomas  
Interface hepatitis, plasma cells 
Treatment  Ursodeoxycholic acid Immunosuppression 
AMA – anti-mitochondrial antibody, SMA – smooth muscle antibody, LKM – liver kidney 




DEFINTION OF OVERLAP 
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Definitions of overlap syndrome are variable and have changed over time as our 
understanding of autoimmune liver disease has developed. Generally, it is agreed that the 
presence of a single feature of another condition (for example AMA positivity in a patient 
with otherwise typical AIH or elevated aminotransferase activity in a patient with classical 
PBC) is not sufficient to diagnose an overlap syndrome. The stringency of the definitions 
applied impacts on the reported frequencies of overlap, and additionally reflect the interest 
and background mechanistic viewpoint of investigators.  If investigators believe that therapy 
with immunosuppression is beneficial then there might be a tendency to apply less stringent 
definitions, whereas if clinicians see overlap presentations as extreme presentations of one 
underlying dominant, frequently biliary, process then there may be a reluctance to reach a 
diagnosis of overlap unless every feature, including response to therapy, is demonstrable for 
an individual patient.  
 
PREVALENCE 
Reported prevalence of PBC-AIH overlap varies depending on definitions used. A commonly 
used set of classifying criteria derived by Chazouilleres et al (3) identified 12 cases of overlap 
amongst 130 consecutive patients diagnosed with PBC (9.2%). Czaja (4) applied the IAIHG 
(International Autoimmune Hepatitis Group) criteria to 37 patients with PBC and found that 
7 (19%) satisfied the criteria for AIH. The timing at which such criteria are applied to patients 
is relevant, as is the appreciation in PBC of a subset of patients with high risk, UDCA non-
responsive disease, that might mimic overlap biochemically (5).  
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PRESENTATION 
Patients with overlap syndromes can present in a number of different ways.  Some may be 
identified at the time of diagnosis (the simultaneous presentation), whilst others have a 
diagnosis of one condition which is stable for a number of years before they develop 
features of another (the sequential presentation). In those with a simultaneous 
presentation, extra care needs to be taken when diagnosing overlap as this is most often a 
reflection of disease variation rather than a true overlap, and many would delay reaching 
such a diagnosis until after the dominant disease process is treated and a repeat evaluation 
is undertaken (case 1). The diagnosis in those with a sequential presentation is often much 
more straightforward and these patients are easier to characterise as having cross-over 
features. As is characteristic of classical AIH, some patients will have an indolent 
presentation (case 2) whilst some can have a much more florid presentation (case 3).   
 
DIAGNOSIS 
Whilst the presence of a deviation from the normally expected features of a condition 
should alert the clinician to the fact that a patient may have overlap, the patient should be 
viewed holistically and no single feature that differs from expected can be used as the sole 
basis for diagnosis of overlap. The most commonly used criteria in suspected PBC-AIH 
overlap was developed by Chazouillieres et al (3) (Table 2). Using these criteria, a diagnosis 
of overlap is proposed if a patient has two out of the three features of PBC as well as two 
out of three features of AIH. These criteria combine biochemical, immunological and 
histological features with biopsy being a mandatory requirement. Perhaps in a reflection of 
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an absent gold standard, these criteria are reported as having a high sensitivity (92%) and 
specificity (97%) for PBC-AIH overlap (6).  
Table 2: Classifying criteria for PBC-AIH overlap 
PBC features 
ALP >2 x ULN or GGT >5 x ULN 
AMA ≥ 1:40 
Liver biopsy showing florid duct lesions
* 
And  
AIH features  
ALT >5 x ULN 
IgG >2 x ULN or positive smooth muscle antibody  
Liver biopsy showing moderate or severe periportal or 
periseptal lymphocytic piecemeal necrosis
* 
 
*histology is mandatory to classify PBC-AIH in this way 
 
The role of autoantibodies 
Establishing the autoantibody profile in patients with autoimmune liver disease is useful in 
diagnosis and carries a prognostic role helping to establish the disease phenotype, risk of 
progression and in some cases response to treatment. They can cause additional confusion 
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for example when a patient with otherwise classical PBC is found to have a positive anti 
SMA. Again, a holistic view of the patient and clinical scenarios is essential.  PBC specific 
antinuclear antibodies can be useful where there is diagnostic doubt (i.e. AMA negative 
disease) with anti-Sp100 and anti-gp210 having a high specificity for PBC (>95%). In addition, 
Nakamura et al (7) demonstrated that anti-gp210 positivity was an independent risk factor 
for progressive disease (including end stage hepatic failure, hepatocellular carcinoma and 
variceal bleeding) and liver transplant and that biopsies from these patients typically 
showed severe interface hepatitis and lobular inflammation. This phenotype can often be 
confused for PBC-AIH overlap. However, gp210 positivity is a marker of a poor response to 
steroids (8).  The significance of anti sp100 positivity is less well understood but is also 
thought to be associated with more rapidly progressive disease (9).  
 
TREATMENT 
Whilst PBC and AIH both fall under the umbrella term of autoimmune liver disease, their 
treatment strategies are distinct. Currently, ursodeoxycholic acid (UDCA) is the only 
treatment licensed for use in PBC (where it is given at a dose of 13-15mg/kg/day), and the 
mainstay of treatment for AIH is immunosuppression initially with corticosteroids, and 
subsequently azathioprine. There is a paucity of randomised data to guide treatment 
guidelines for overlap.  
In practice, treatment is commonly guided by the mode of presentation with different 
strategies employed for those with simultaneous presentations than for those with distinct 
sequential presentations.  In a patient who has overt features of both PBC and AIH at first 
presentation it is often best to treat with UDCA for six months and then re-evaluate, with 
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some then considering the addition of corticosteroids if liver biochemical parameters 
continue to support the presence of a potentially corticosteroid responsive hepatitis. 
However, the patient demographics are important; we now recognise, for example, that 
patients diagnosed with PBC before the age of 50, have a high (50%) chance of treatment 
failure with UDCA, highlighting a more aggressive disease perhaps better considered to be a 
hepatitic PBC rather than PBC-AIH overlap with the former not responding to steroids.  
For a patient with established PBC who subsequently develops features of AIH are offered 
treatment as per standard AIH guidelines, however with close attention to demonstrating 
response.  Exclusion of drug induced liver injury is important, as is identification of AMA 
negative PBC. The latter group were classically first described as ‘autoimmune cholangitis’ 
precisely because they had elevated IgG values and were AMA negative (10). 
 
WHEN TO REFER FOR SPECIALIST OPINION  
Due to the lack of specific diagnostic criteria for overlap, the variety of modes of 
presentation and the relative rarity of the condition, it can often be difficult to positively or 
negatively determine the diagnosis of an overlap syndrome. This can lead to under 
treatment with the risk of uncontrolled disease progressing to fibrosis and cirrhosis or over 
diagnosis leading to patients receiving escalating immunosuppression and the associated 
risk of treatment side effects. Referral to a specialist centre with a high volume caseload of 
patients with autoimmune liver disease should be considered in the following 
circumstances: 
• Patients with UDCA unresponsive disease 
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• Patients diagnosed with PBC under the age of 50 
• Patients with potential overlap where there is diagnostic uncertainty or where 
immunosuppression is ineffective (ie failure of AST or ALT to fall despite an adequate 






TAKE HOME MESSAGES 
• Suspect the diagnosis of overlap in any patient with features of more than one 
condition either at diagnosis or over the disease course. 
• There is no single diagnostic feature for overlap and the patient should be viewed 
individually, over time, with a focus on the dominant histologic process in particular.  
• Be cautious when diagnosing overlap in the young patient with PBC and 
inflammatory features on biochemistry and histology.  
• Liver biopsy, with review by a specialist histopathologist, is essential in the 
evaluation of overlap presentations. 
• If in doubt, refer to a multi-disciplinary expert team for advice. 
• Be cognisant that age, gender and ethnicity can impact disease presentation in 
autoimmune liver disease. 
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CASE EXAMPLES  
Case 1 
Miss A presented age 34 with pruritus and cholestatic jaundice (bilirubin 113, ALP 286). 
Autoantibody screen showed a positive AMA, SMA was negative and IgG was within normal 
range. She was diagnosed with PBC and commenced on UDCA. After 4 months of treatment 
with UDCA her ALP remained raised at 379 and her ALT was mildly elevated at 56. She 
underwent a liver biopsy which showed interface activity and portal inflammation. She was 
given a diagnosis of overlap syndrome and was commenced on prednisolone but this was 
stopped after three months. This was followed by a further rise in ALT to 97. As such, 
prednisolone was restarted and azathioprine added. Despite remaining on prednisolone 
20mg and azathioprine being titrated up to 1.5mg/kg/day her ALT remained raised. Her 
prednisolone was further increased to 30mg and she was referred for tertiary opinion. At 
this time, she was symptomatic from her steroid use. Her original biopsy was reviewed and 
whilst it was felt that inflammatory activity was present this could be consistent with biliary 
disease. Extended serology showed positive ANA 1:100 (multidot pattern), sp100 positive, 
gp210 negative. The overall impression was that this was not overlap and 
immunosuppression was withdrawn and UDCA was continued. The patient’s biochemistry 
remained abnormal and she is likely to progress to transplant unless new therapies emerge.  
Learning points: this case illustrates a young patient who met diagnostic criteria for PBC but 
with some features that are inconsistent with classic PBC. It is recognised that patients 
diagnosed with PBC before the age of 50 have a 50% chance of being UDCA treatment non-
responders and that non-response is frequently characterised on the basis of elevated 
serum aminotransferase activity (11). These patients, sometimes referred to as hepatitic 
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variant PBC, often have features that suggest overlap syndrome (in this case raised ALT and 
biopsy features) and differentiating between the two can be complex. In these cases, 
involvement of a centre with experience of complex autoimmune disease is vital with expert 
opinion from a specialist hepatologist and histopathologist.  Whilst some argue that in such 
“hepatitic PBC” presentations, with interface hepatitis, that Budesonide has a favourable 
effect, randomised controlled data to this effect is still lacking. There is, however, emerging 
evidence for second line therapies for UDCA treatment unresponsive PBC such as the FXR 
agonist obeticholic acid (12). Whilst this patient was not responsive to UDCA by established 
criteria, there is no evidence that UDCA should be stopped in these cases and second lines 
therapies when available are used in addition to rather than instead of UDCA. It is also 
important to note in this patients that use of immunosuppression is a frequent contra-
indication to inclusion in a clinical trial, which therefore means that inappropriate use of 




Mrs. B was diagnosed at the age of 58 with PBC. Extended serology showed AMA positivity 
(titre 1:100), ANA negative, sp100 and gp210 negative with a normal IgG and raised IgM. 
She was commenced on treatment with UDCA and her ALP normalised. In 2013 
(approximately 6 years after her original diagnosis) she developed symptoms of poor 
appetite, malaise and diarrhoea. Blood tests performed in primary care showed a 
predominantly hepatitic picture (Bilirubin 15, ALT 255, AST 150, ALP 106, albumin 42, GGT 
74). She underwent a viral screen (negative for CMV, EBV, Hepatitis A, B, C, E) and repeat 
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immunology (SMA >1:160, IgG 19.04, IgM 7.9). Drug history revealed no culprit medications. 
Biopsy was consistent with AIH with confluent/bridging necrosis, plasma cells, interface 
hepatitis and rosettes. She remained on UDCA and was started on prednisolone 20mg with 
the addition of azathioprine 50mg once biochemical response to steroids was achieved and 
titrated to a dose of 150mg.  The patient achieved normal tests. 
Learning points: this case illustrates a consecutive diagnosis of two diagnoses (PBC followed 
by AIH) which is the most common type of overlap seen in the outpatient setting. Given the 
time separating the presentations, it is appropriate to investigate the new liver biochemical 
changes as for any patient; viral screen, drug screen, autoimmune screen. In this case there 
were clear features of AIH and treatment was commenced as per standard guidelines.   
 
Case 3 
Mrs. C had a known diagnosis of PBC and was on treatment with UDCA at a dose of 1000mg 
daily. In late 2014 she presented for her routine out patient follow up and was found to be 
jaundiced with grade 1 encephalopathy. The patient reported that she had first noticed the 
jaundice two weeks prior associated with loose stools and vomiting. There was no history of 
new medications (either prescribed or over the counter) and no recent travel. Blood tests at 
presentation showed bilirubin 258, ALT 1211, ALP 141, albumin 28, INR 3.9. Blood tests 
taken one month prior showed bilirubin 9, ALT 246, ALP 170, INR 1.0, albumin 39. Non 
invasive liver screen was performed (Hepatitis A, B, C, E, CMV, EBV negative; IgG 25, IgM 
11.77, IgA 3.43; AMA positive >1:100, SMA negative, ANA negative, gp210 and sp100 
negative). She was commenced on Tazocin and Fluconazole and transferred to her nearest 
liver transplant centre where she was admitted to critical care due to worsening 
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encephalopathy. She was placed on the super urgent transplant list and received a donor 
liver two days later. Explant histology revealed submassive necrosis. Biliary features were 
present but with mild fibrosis only.   
Learning points: A florid presentation of AIH on the background of established PBC is rare. 
Whilst most will present like case 2, it is important to recognise acute AIH in the context of a 
patient with underlying PBC and to differentiate from a decompensation of PBC. 
Management should be as for any patient with acute AIH and liver transplant assessment 
should be considered.  In this case the prior presence of early PBC was not a 
contraindication to super-urgent registration for transplantation given the distinct clinical 
presentation of an acute and evolving severe liver injury. 
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BEST OF FIVE QUESTIONS 
Question 1 
A 38-year-old female is referred by her GP with abnormal liver biochemistry tests having 
presented with fatigue and pruritus. She is a smoker with a 10 pack year history and drinks 
approximately 6-10 units of alcohol per week. Her liver biochemistry shows bilirubin 34, ALT 
312, ALP 283, albumin 45, GGT 178. A non invasive liver screen is performed.  
Which of these features is not one of the criteria set out by Chazouilleres for the diagnosis 
of PBC-AIH overlap? 
A – AMA titre 1:160 
B – ALP 273 
C – ALT 312 
D – decrease in ALT to 150 and ALP to 130 after 4 months of treatment with UDCA 





This scenario describes a young patient presenting with classical symptoms associated with 
PBC (fatigue and itch) but a pattern of liver biochemistry that is mixed with both a raised 
ALP and ALT. Answers A, B, C, E are all elements of Chazouilleres criteria for overlap. The 
response to UDCA treatment suggests that this is a hepatitic PBC rather than overlap. 
 
Question 2 
Mrs. D was diagnosed with PBC at the age of 52 and commenced on UDCA at a dose of 
14mg/kg/day. After nine months of treatment her liver biochemistry was entirely normal. 
She is reviewed in clinic on an annual basis. At a routine follow up she is noted to be 
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clinically jaundiced. On questioning she reports that she has been off work from her job as a 
nurse for the last 2 weeks as she felt unwell with joint aches and pains following her 
returned from holiday in Thailand 3 weeks ago. She was treated for a dental infection two 
weeks ago. Her blood tests are shown below: 
Bilirubin 87, AST 346, ALT 234, ALP 157, albumin 35 
AMA 1:160, SMA 1:80, IgG 21 
Hb 112, WCC 12.3, platelets 156, MCV 102 
Hepatitis B surface antigen negative, hepatitis B surface antibody positive, hepatitis B core 
antibody negative.  
Which of these is the least likely cause of her acute illness? 
A. Alcoholic hepatitis  
B. Augmentin related liver injury 
C. Hepatitis A  
D. Immunisation against Hepatitis B 
E. PBC/AIH overlap 
 
 
Answer B:  
 
This scenario describes a patient with established PBC who develops a new onset jaundice 
with a predominantly hepatitic pattern. All of the above conditions can cause a hepatitic 
jaundice. AST is higher than ALT and MCV is raised which could suggest alcoholic hepatitis. 
Given her profession she is likely to have been immunized against hepatitis B which explains 
the serology. Hepatitis A is a risk given her recent travel. Her blood tests could be consistent 
with overlap although biopsy is mandatory for the diagnosis. Whilst Augmentin can cause a 
hepatitic pattern it is more commonly associated with cholestatic jaundice.  
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